Voyager Therapeutics, Inc.
VYGRNasdaqCIK 1640266HealthcareFiscal year ends Dec 31
Reports and events: 174 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2112:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-427224 |
| 2026-08-0620:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001640266-26-000007 |
| 2026-08-0620:01 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001640266-26-000006 |
| 2026-07-1312:44 ET | 8-K | 8.01 Other events | 0001104659-26-082906 |
| 2026-06-1020:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-072324 |
| 2026-06-0112:00 ET | 8-K | 8.01 Other events | 0001104659-26-068591 |
| 2026-05-0720:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057115 |
| 2026-05-0720:04 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-057097 |
| 2026-04-2820:00 ET | DEF 14A | Proxy statementPeriod 2026-06-09 | 0001104659-26-050297 |
| 2026-04-2120:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-26-045997 |
| 2026-03-0920:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-025201 |
| 2026-03-0920:02 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-025197 |
| 2026-02-1213:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001104659-26-013897 |
| 2026-01-0813:16 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-001955 |
| 2025-11-1013:01 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-108846 |
| 2025-11-1013:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-108841 |
| 2025-09-0211:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-085977 |
| 2025-08-0620:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-010511 |
| 2025-08-0620:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-010507 |
| 2025-06-0520:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-25-056835 |
| 2025-05-0620:02 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-006484 |
| 2025-05-0620:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-006482 |
| 2025-04-2320:01 ET | DEF 14A | Proxy statementPeriod 2025-06-03 | 0001558370-25-005254 |
| 2025-03-1120:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-002703 |
| 2025-03-1120:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-002702 |
| 2025-02-1112:07 ET | 8-K | 8.01 Other events | 0001104659-25-011155 |
| 2024-11-1221:01 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-015304 |
| 2024-11-1221:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-015299 |
| 2024-09-0512:06 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-24-097152 |
| 2024-08-0620:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011073 |
| 2024-08-0620:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-011071 |
| 2024-06-1311:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-24-071048 |
| 2024-06-0620:04 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-069063 |
| 2024-05-1611:05 ET | 8-K | 8.01 Other events | 0001104659-24-062257 |
| 2024-05-1320:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-007953 |
| 2024-05-1320:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-007951 |
| 2024-04-2521:20 ET | DEF 14A | Proxy statementPeriod 2024-06-05 | 0001558370-24-005793 |
| 2024-04-0220:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-24-042502 |
| 2024-03-1311:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-033726 |
| 2024-02-2821:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-001988 |
| 2024-02-2821:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-24-001987 |
| 2024-01-0821:49 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-002271 |
| 2024-01-0212:05 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 8.01 Other events | 0001104659-24-000084 |
| 2023-12-0612:04 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-123809 |
| 2023-11-0621:01 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-017754 |
| 2023-11-0621:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-23-017753 |
| 2023-08-1620:18 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-23-092566 |
| 2023-08-0311:15 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-013058 |
| 2023-08-0311:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-23-013047 |
| 2023-07-1012:04 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-079340 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.